(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Pick A Trade-in vehicle Stage - 2America's Confided in Cooler in 2024
- 3Poland identifies two Ukrainian suspects in railway sabotage blast
- 4Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 5Ocean side Objections: Staggering Waterfront Breaks
- Vote In favor of Your Favored Kind Of Cheddar
- Why a German YA romance you’ve never heard of is leaving everyone obsessed
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Vote in favor of the pasta that makes good dieting pleasant!
- Embrace the Outside: Exercises and Entertainment
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Moscow accuses Berlin of stifling the opposition
- Top Breakfast Food: What's Your Morning Pleasure?
- Viable Correspondence: Building Solid Connections
